← Pharmacy curriculum
Module 1288 lessonsRxPrep 2023 Chapter 39 reconciled with current AAD cold sore guidance, current DailyMed docosanol, acyclovir, penciclovir, buccal acyclovir, and valacyclovir labeling, and systematic antiviral evidence

Herpes Labialis

Connect HSV biology, recurrent-lesion recognition, transmission control, early episodic treatment, antiviral pharmacology, renal safety, symptom care, prevention, and urgent escalation.

01

Explain primary infection, neuronal latency, reactivation, viral replication, and the limits of antiviral therapy.

02

Differentiate recurrent herpes labialis from primary gingivostomatitis, common mimics, ocular disease, and eczema herpeticum.

03

Counsel on direct contact, asymptomatic shedding, autoinoculation, household protection, and infant or immunocompromised exposure.

04

Select early topical or oral episodic therapy from product labeling, timing, age, route, immune status, and expected benefit.

05

Apply renal dose adjustment, hydration, nephrotoxicity, neurotoxicity, interaction, pregnancy, lactation, and pediatric safeguards.

06

Design symptom, trigger, recurrence, prevention, monitoring, and referral plans that reflect disease burden and patient goals.

128.01

Follow HSV From Entry to Reactivation

HSV replicates at a mucocutaneous site, enters sensory neurons, establishes lifelong latency, and can reactivate along the same neural distribution.

What to learn
  • HSV-1
  • HSV-2
  • Latency
  • Reactivation
  • Viral DNA polymerase
Viral lifecycleFollow HSV from mucocutaneous entry to neuronal latency and episodic reactivation
01EntrySkin or mucosa

Local replication begins

02TravelSensory axon

Virus reaches the ganglion

03LatencyNeuronal genome persists

No current eradication therapy

04ReturnReactivation to the lip

Prodrome can precede vesicles

Separate type from site

HSV-1 commonly causes recurrent herpes labialis, but either HSV type can infect oral or genital sites. Anatomy, exposure, and testing matter more than a type stereotype.

Establish latency

After local replication, HSV travels through sensory axons and persists in a ganglion. Current antivirals do not remove this neuronal reservoir.

Recognize reactivation

Illness, fatigue, stress, tissue trauma, dental work, hormonal change, and strong sunlight can trigger recurrence in susceptible patients, but triggers vary.

Target replication

Acyclovir and related nucleoside analogs require intracellular activation and inhibit viral DNA polymerase. Their value is greatest while viral replication is active.

0 of 1 answered
01Why can a cold sore recur after apparently complete healing?
Answer every question to submit.
128.02

Distinguish a Familiar Recurrence From a Dangerous Pattern

A typical recurrence is localized and familiar. Diffuse oral disease, eye symptoms, neurologic findings, immune compromise, and atypical lesions change the pathway.

What to learn
  • Prodrome
  • Grouped vesicles
  • Gingivostomatitis
  • Keratitis
  • Differential
Pattern recognitionSeparate recurrent labial HSV from primary disease, mimics, and urgent complications
01RecurrentFamiliar prodrome

Grouped vesicles near the lip

02PrimaryDiffuse oral disease

Fever and impaired intake

03MimicUlcer, fissure, crust

Diagnosis changes treatment

04UrgentEye or neurologic symptoms

Protect sight and life

Recognize recurrence

Tingling, itching, burning, or pain often precedes grouped vesicles near the vermilion border. Lesions rupture, ooze, crust, and usually heal without scarring in an immunocompetent patient.

Recognize primary disease

Primary oral HSV can produce diffuse painful gingivostomatitis, fever, lymphadenopathy, odynophagia, and reduced intake, especially in children.

Protect the eye and brain

Eye pain, photophobia, visual change, gritty tearing, severe headache, confusion, seizure, or focal neurologic findings require urgent evaluation.

Keep the differential open

Aphthae, impetigo, angular cheilitis, contact dermatitis, trauma, candidiasis, hand-foot-and-mouth disease, and malignancy can mimic parts of the course.

0 of 1 answered
01Which presentation requires urgent evaluation?
Answer every question to submit.
128.03

Break Transmission Without Promising Zero Risk

Active lesions and secretions raise transmission risk, but HSV can also shed without visible disease. Precautions reduce risk rather than eliminating it.

What to learn
  • Contact
  • Secretions
  • Asymptomatic shedding
  • Autoinoculation
  • Hand hygiene
Break the contact chainVisible lesions raise risk, but shedding and transfer cannot be judged perfectly by appearance
01ContactKissing and oral exposure

Avoid during outbreaks

02FomiteLip and personal products

Do not share

03HandsLesion to eye or skin

Wash after contact

04SheddingCan occur without lesions

Risk reduction is not zero risk

Avoid high-risk contact

During an outbreak, avoid kissing, oral contact, and sharing drinks, utensils, towels, razors, cosmetics, or lip products.

Control hand transfer

Do not pick lesions. Wash hands after touching a lesion or applying medication, and keep contaminated fingers away from eyes, genital skin, broken skin, and other people.

Explain shedding

Visible healing lowers risk, but appearance cannot prove that viral shedding has stopped. A lack of lesions does not guarantee zero transmission.

Protect vulnerable contacts

Newborns, immunocompromised people, and children with atopic dermatitis can develop serious disease. Contact precautions and early clinical advice matter.

0 of 1 answered
01Which counseling statement is most accurate?
Answer every question to submit.
128.04

Treat at the Prodrome, Not at the End of the Episode

Topical products provide modest benefit when started early. Site, age, immune status, schedule, and application burden determine whether they fit.

What to learn
  • Docosanol
  • Acyclovir cream
  • Penciclovir
  • Early treatment
  • Application technique
Treat the replication windowTopical benefit depends on early recognition, correct site, and sustained application
01ProdromeTingle, itch, burn

Start immediately

02DocosanolOTC external use

Five times daily until healed

03PenciclovirEvery two waking hours

Continue four days

04AcyclovirCutaneous use only

Follow exact product label

Use docosanol within its label

Current OTC docosanol 10 percent labeling treats external cold sores on the face or lips. Apply five times daily from the first tingle, redness, bump, or itch until healed, following the exact product age and warning language.

Use acyclovir cream correctly

Acyclovir cream is for recurrent herpes labialis on the lips and around the mouth in immunocompetent patients at least 12 years old. Keep it out of the eye, mouth, and nose.

Plan penciclovir frequency

Penciclovir 1 percent cream is applied every two hours while awake for four days and should begin at the earliest sign. The frequent schedule and modest average benefit must be understood.

Prevent contamination

Use clean hands or a clean cotton-tipped applicator, dab rather than scrub, wash hands afterward, and do not share the product.

0 of 1 answered
01When should topical episodic treatment begin?
Answer every question to submit.
128.05

Select an Antiviral Regimen by Indication

Oral and buccal therapies can improve convenience and efficacy, but cold sore regimens cannot be borrowed from genital herpes or zoster.

What to learn
  • Valacyclovir
  • Acyclovir
  • Buccal tablet
  • DNA polymerase
  • Indication-specific dosing
Match formulation to the episodeIndication, timing, route, immune status, and renal function define the regimen
01ValacyclovirTwo doses in one day

Verify renal table

02AcyclovirActivated in infected cells

Inhibits viral DNA polymerase

03BuccalSingle upper-gum dose

Apply within one hour of prodrome

04RouteOral versus topical

Balance benefit and burden

Use the labeled valacyclovir course

A current label uses valacyclovir 2 grams every 12 hours for one day in adults and patients at least 12 years old. Start at the earliest symptom and do not exceed one day for this indication.

Understand prodrug pharmacology

Valacyclovir is converted to acyclovir and improves oral bioavailability. Intracellular acyclovir triphosphate inhibits viral DNA polymerase and terminates DNA-chain elongation.

Use buccal acyclovir as designed

Acyclovir 50 mg buccal tablet is a single dose for immunocompetent adults, placed on the upper gum canine-fossa region within one hour of prodrome. Do not crush, chew, suck, or swallow it.

Choose route deliberately

Consider onset, recurrence burden, renal function, immune status, swallowing, application burden, access, expected modest benefit, and preference.

0 of 1 answered
01What is the labeled valacyclovir cold sore regimen for a patient with normal renal dosing?
Answer every question to submit.
128.06

Connect Renal Clearance to Dose and Toxicity

Acyclovir exposure rises when renal clearance falls. Hydration, dose adjustment, nephrotoxins, age, dialysis, and immune status shape safety.

What to learn
  • Creatinine clearance
  • Acute kidney injury
  • Neurotoxicity
  • Hydration
  • Severe reactions
Clear the antiviral safelyRenal clearance connects hydration, dose, kidney injury, and neurologic toxicity
01KidneyCalculate clearance

Adjust the indication-specific dose

02WaterPrevent avoidable concentration

Respect heart and kidney limits

03BrainConfusion, tremor, seizure

Consider accumulation

04HostImmune compromise

Standard self-care evidence may not apply

Calculate renal function

Use the current product label and the institution's accepted renal estimate. A normal-looking serum creatinine can hide low clearance in an older or low-muscle-mass patient.

Protect the kidney

Dehydration, excessive dose, rapid high exposure, existing kidney disease, and nephrotoxins increase acyclovir crystal nephropathy and acute kidney injury risk.

Recognize neurotoxicity

Confusion, agitation, hallucinations, tremor, myoclonus, or seizures during treatment can reflect accumulation and require urgent evaluation.

Escalate serious host and skin findings

Current valacyclovir labeling includes severe cutaneous reactions and TTP or HUS in specific severely immunocompromised high-exposure settings. Rash with mucosal or systemic illness, hemolysis, thrombocytopenia, or renal decline needs prompt care.

0 of 1 answered
01Which patient has the greatest risk of acyclovir accumulation?
Answer every question to submit.
128.07

Support Healing Without Damaging the Barrier

Comfort measures and trigger reduction can help, but caustic remedies and unproven supplements can delay effective care.

What to learn
  • Cool compress
  • Pain relief
  • Lip barrier
  • Sun trigger
  • Lysine
Protect the healing barrierComfort care should reduce pain and triggers without creating new tissue injury
01CoolCompress and hydration

Support comfort

02BarrierBland lip protection

Avoid picking

03SunSPF 30 plus lip balm

Useful when sunlight is a trigger

04ClaimsLysine and home remedies

Do not replace proven care

Use gentle comfort care

Cool compresses, bland lip protection, adequate intake, and age-appropriate analgesia can improve comfort. Avoid picking or peeling the crust.

Avoid tissue injury

Alcohol, bleach, acids, aggressive exfoliation, and other caustic home remedies can worsen pain, delay healing, and obscure secondary infection.

Address sunlight triggers

For patients with sun-triggered recurrences, use broad-spectrum SPF 30 or higher lip balm and layered photoprotection. Do not promise complete prevention.

Counsel on supplements honestly

Lysine is commonly used, but current evidence does not establish it as a reliable substitute for antiviral treatment or suppression. Review product quality, cost, interactions, and kidney or reproductive considerations.

0 of 1 answered
01Which supportive measure is most appropriate?
Answer every question to submit.
128.08

Escalate by Burden, Host, and Complication

Frequency, severity, functional impact, immune status, atopic dermatitis, eye symptoms, duration, and infection determine prevention and referral.

What to learn
  • Suppressive therapy
  • Eczema herpeticum
  • Immune compromise
  • Secondary infection
  • Pregnancy and pediatrics
Escalate by burden and riskFrequency is only one dimension of prevention and referral
01BurdenEpisodes and function

Consider suppressive planning

02ImmuneProlonged or atypical disease

Test and treat earlier

03EczemaMonomorphic painful spread

Urgent systemic care

04FollowEye, infection, duration

Know the red flags

Measure recurrence burden

Document episode frequency, duration, pain, missed work or school, triggers, psychosocial effect, and response. Frequent or disabling disease can justify clinician-directed suppression or pre-exposure therapy.

Recognize eczema herpeticum

Painful monomorphic vesicles or punched-out erosions spreading across atopic dermatitis, especially with fever or eye symptoms, require urgent systemic antiviral care.

Protect immunocompromised patients

Prolonged, extensive, atypical, resistant, or disseminated disease warrants testing, systemic therapy, and specialist input rather than routine self-care.

Use product-specific reproductive and pediatric evidence

Do not use retired pregnancy letters or adult self-care dosing for young children. Assess pregnancy timing, lactation, infant contact, age, weight, renal function, and exact labeling.

0 of 1 answered
01Which finding most strongly suggests eczema herpeticum?
Answer every question to submit.

Check the connections.

Each attempt draws 10 questions from the complete 112 question bank.

112 questions in this module bank10 questions per attempt

Each attempt draws a fresh set and rearranges the answer choices.

Current clinical foundation.

Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.

  1. AAD Cold Sore Overview
  2. AAD Cold Sore Diagnosis and Treatment
  3. DailyMed Docosanol 10 Percent Cream
  4. DailyMed Valacyclovir Label
  5. DailyMed Acyclovir Cream Label
  6. DailyMed Penciclovir Cream Label
  7. DailyMed Buccal Acyclovir Label
  8. Antiviral Treatment Systematic Review
  9. Herpes Labialis Prevention Cochrane Review
PharmacyOpen tools